| Document |
Document Title |
|
WO/2004/022528A2 |
The present invention relates to compounds of Formula (I), and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological, neuropsychia...
|
|
WO/2004/022530A1 |
The invention provides a compound containing a head group based on urea, glycerol or glycerate and a tail selected from the group consisting of a branched alkyl chain, a branched alkyloxy chain or an alkenyl chain. The compounds may be u...
|
|
WO/2004/022529A2 |
The present invention relates to novel diarylurea derivatives represented by general formula (I) useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as f...
|
|
WO/2004/020400A1 |
This invention pertains to certain enzyme (CPG2) activated self-immolative nitrogen mustard prodrugs, which are useful in enzyme prodrug therapy (EPT), such as ADEPT and GDEPT, for the treatment of proliferative conditions, such as cance...
|
|
WO/2004/013089A1 |
Fluorinated urethane compounds represented by the general formula (1) can impart high water- and oil-repellency: [Rf-A1-(X1(OH))-(Y1)a-OC(=O)NH-]m I [-NHC(=O)O-Y2]n [-NHC(=O)O-((ClCH2-)X2O)b-R1]k (1) wherein I is a group derived from a p...
|
|
WO/2004/009558A2 |
The invention encompasses ureido substituted benzoic acid compounds of structure (I), compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these...
|
|
WO/2004/007459A2 |
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatme...
|
|
WO/2004/007407A2 |
The present invention includes methods and compositions for increasing the fluorous nature of an organic compound by reacting it with at least one fluorous compound to produce a fluorous tagged organic compound. The increased fluorous na...
|
|
WO/2004/007436A1 |
The invention relates to a method for producing tetra-substituted ureas by reacting the corresponding amines with phosgene in the presence of an aqueous inorganic base at a temperature ranging of from 0 to 150 °C. According to the inven...
|
|
WO/2004/005478A2 |
This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA cons...
|
|
WO/2004/002941A1 |
The invention concerns cosmetic or dermopharmaceutical compositions comprising tyramine derivatives and their salts. The invention also concerns the method for preparing same and use thereof for reducing pigmentation.
|
|
WO/2004/002944A1 |
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
|
|
WO/2004/002940A1 |
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.
|
|
WO/2004/000295A1 |
A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group -(CH2...
|
|
WO/2003/105846A1 |
The present invention relates to compounds of formula I, wherein X, Q, W, R1, R2 and R3 are as defined in the claims, which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. T...
|
|
WO/2003/103651A1 |
The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for...
|
|
WO/2003/104188A1 |
The invention relates to N-benzoylureidocinnamate derivatives of formula (I), where R1-R11 have the meanings given in the claims, the physiologically acceptable salts and method for production thereof. The compounds are suitable as anti-...
|
|
WO/2003/101927A1 |
Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A...
|
|
WO/2003/102592A2 |
There is disclosed a method for selectively binding micromolecules having a lysine functionality comprising the steps of: providing a sample containing one or more species of macromolecules, each having a lysine functionality; providing ...
|
|
WO/2003/102044A2 |
Low-cure powder coating compositions are disclosed. The compositions comprise a polyepoxide and a material having the structure: formula (I) wherein R1 is an organic radical having 6 to 25 carbon atoms; R2 is an organic radical having 1 ...
|
|
WO/2003/099776A1 |
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or i...
|
|
WO/2003/097586A1 |
This invention is directed to vanilloid receptor VR1 ligands of formula (1). More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment an...
|
|
WO/2003/097587A2 |
The invention relates to a novel class of gelling agents, to a process of preparing said agents, to the use of said agents to prepare gels, and to the gels thus obtained. A gelling agent or thickener according to the invention comprises ...
|
|
WO/2003/097619A1 |
A novel class of compounds of the general formula (I), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the...
|
|
WO/2003/095420A1 |
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...
|
|
WO/2003/092670A1 |
Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein teh substituents have the values mentioned herein, are bombesin antagonists, which have utility in variety of therapeutic areas including male and female sexual...
|
|
WO/2003/093250A2 |
The invention provides compounds of Formula I: (1) these compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases...
|
|
WO/2003/093224A1 |
Compounds of the formula (R5)m-(R6A)-2-(R4)-1-[N= C(R1)N(R2)(R3)]benzene and their agriculturally suitable salts, are disclosed which are useful as fungicides, wherein R1 is H, OH, SH, SO3H, CN, -OR7 or -SR7; C1-C10 alkyl, C2-C10 alkenyl...
|
|
WO/2003/091204A1 |
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...
|
|
WO/2003/091287A1 |
Compounds of formula (I), wherein Y is, for example, C3-C,12alkylene, butenylene, butynylene, or C4-C,12alkylene interrupted one or more times by non-consecutive -O- or -NR2-; R1 is a reactive group selected from OH, SH, NR3R4, -(CO)-OH,...
|
|
WO/2003/089404A1 |
The present invention relates to naphthylamide compounds and their ability to act as potassium channel openers.
|
|
WO/2003/089615A2 |
Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a com...
|
|
WO/2003/089405A1 |
The present invention relates to derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition, more particularly the compounds of the present invention specifically inhibit the activation of T lymphoc...
|
|
WO/2003/088915A2 |
The present invention is directed to novel phenytoin derivative compounds and the use of such compounds as sodium channel blockers. Such compositions have utility as anti-cancer agents and can be used to limit or prevent PCa growth and/o...
|
|
WO/2003/087045A1 |
Novel compounds of Formula (I) which modulate MCH activity are disclosed, in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 is a lower alkoxy group; R2 is an R1 group or hydrogen, an OH or an NH2 group, Q together with the c...
|
|
WO/2003/087044A2 |
Novel compounds of formula (I) which modulate MCH activity are disclosed, in which A is a linker; B is a connecting moiety; Ar1 and Ar2 are aryl or heteroaryl groups; R1 and R2 are hydrogen, halogen atoms, CF3, OCF3, SCF3, SCH3, nitrile,...
|
|
WO/2003/087046A1 |
Novel compounds of formula (I) which modulate MCH activity are disclosed in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 and R2 are hydrogen, straight or branched alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylc...
|
|
WO/2003/084997A1 |
Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method. The present invention also includes pharmaceutical compositions. In more deta...
|
|
WO/2003/084922A1 |
The invention relates to acyl-4-carboxyphenylurea derivatives, the physiologically-acceptable salts, physiologically-functional derivatives thereof and compounds of formula (I), where the groups have the given meanings, the physiological...
|
|
WO/2003/084923A1 |
The invention relates to acyl-3-carboxyphenylurea derivatives, physiologically-acceptable salts, physiologically-functional derivatives thereof and compounds of formula (I), where the groups have the given meanings, the physiologically-a...
|
|
WO/2003/082205A2 |
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...
|
|
WO/2003/082777A2 |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as glucocorticoid receptor modulators. The compounds of the instant invention are ligands for glucocorticoid receptors and as such may be ...
|
|
WO/2003/079984A2 |
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms...
|
|
WO/2003/080554A2 |
A compound represented by the following general formula (IA) or a salt thereof: wherein Ar¿1? represents hydrogen atom or an aryl group having at least one iodine atom as a substituent; Ar¿2? represents an aryl group having at least on...
|
|
WO/2003/077847A2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
WO/2003/078376A1 |
A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough.
|
|
WO2003029199A9 |
Novel benzene derivatives represented by the general formula (||), which exhibit vanilloid receptor agonism and are useful as preventive and therapeutic drugs for pollakisuria and urinary incontinence, analgesic, or the like: (||) wherei...
|
|
WO/2003/076397A1 |
The present invention relates to a compound formula [I] wherein R1 and R5 are each independently hydrogen, halogen, lower alkyl, etc., R2 is hydrogen or an amino protective group, x is bond,-o-o,-O-CH2-, etc., y is in which Z is bond, -0...
|
|
WO/2003/075857A2 |
Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.
|
|
WO/2003/075853A2 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ tra...
|
